JAK1 and acute lymphoblastic leukemia: Currently, a phase II trial of the JAK1/2 inhibitor ruxolitinib in combination with standard multi-agent chemotherapy for the treatment of B-precursor ALL in children is running and evaluates the safety and efficacy of this combination (NCT02723994).